Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions

Posted on May 6th, 2016 by

Pharmacovigilance

Medical-Literature

After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail.  Continue reading “The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions” »

Using Text Mining to Find Treatments for Rare Diseases

Posted on May 5th, 2016 by

Pharma R&D

Findacure UK Cure CHI

When you compare PubMed search results for rare diseases, such as “congenital hyperinsulinism” (767), schwannomatosis (250) or “Mabry syndrome” (34), to that of “diabetes” (542,987), “heart attack” (217,694) or “obesity” (237,307), the disparity in attention becomes much more obvious. Continue reading “Using Text Mining to Find Treatments for Rare Diseases” »

Introducing ‘The Hive’

Posted on May 4th, 2016 by

Pharma R&D

Elsevier Hive

Fifty-four percent. That’s the percentage of “all active drugs” sourced via open innovation models for the 12 largest biopharma company pipelines in 2014. Continue reading “Introducing ‘The Hive’” »

Drug Repurposing for Rare Diseases

Posted on April 27th, 2016 by

Pharma R&D

Dr Nicolas Sireau, Findacure

Elsevier’s partnership with a UK charity Findacure started last year with a very touching and inspirational talk from Dr. Nick Sireau, a parent of two children diagnosed with alkaptonuria. Very soon after his first child was born, Nick found himself Continue reading “Drug Repurposing for Rare Diseases” »

Biosimilars and Pharmacovigilance: What You Need to Know—and Do—Now

Posted on April 26th, 2016 by

Pharmacovigilance

injection

A few weeks ago, the US FDA approved Inflectra (infliximab-dyyb), a biosimilar to infliximab. This is the second US biosimilar approval, suggesting others may soon be on the way—good news for companies with biosimilars pending approval and in development. Continue reading “Biosimilars and Pharmacovigilance: What You Need to Know—and Do—Now” »

The Essentials of Pharmacovigilance

Posted on April 19th, 2016 by

Pharmacovigilance

PVblog

Elsevier is attending the World Drug Safety Congress in Chicago this week—an important part of the pharmaceutical industry calendar that brings together experts Continue reading “The Essentials of Pharmacovigilance” »

  1. 1
  2. …
  3. 44
  4. 45
  5. 46
  6. 47
  7. 48
  8. …
  9. 56


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.